Cargando…
α(v)β(3) integrin-targeted micellar mertansine prodrug effectively inhibits triple-negative breast cancer in vivo
Antibody-mertansine (DM1) conjugates (AMCs) are among the very few active targeting therapeutics that are approved or clinically investigated for treating various cancers including metastatic breast cancer. However, none of the AMCs are effective for the treatment of triple-negative breast cancers (...
Autores principales: | Zhong, Ping, Gu, Xiaolei, Cheng, Ru, Deng, Chao, Meng, Fenghua, Zhong, Zhiyuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5667790/ https://www.ncbi.nlm.nih.gov/pubmed/29138558 http://dx.doi.org/10.2147/IJN.S146505 |
Ejemplares similares
-
Photoactivatable prodrug for simultaneous release of mertansine and CO along with a BODIPY derivative as a luminescent marker in mitochondria: a proof of concept for NIR image-guided cancer therapy
por: Tiwari, Rajeshwari, et al.
Publicado: (2020) -
Mertansine Inhibits mRNA Expression and Enzyme Activities of Cytochrome P450s and Uridine 5′-Diphospho-Glucuronosyltransferases in Human Hepatocytes and Liver Microsomes
por: Choi, Won-Gu, et al.
Publicado: (2020) -
Targeted inhibition of human hematological cancers in vivo by doxorubicin encapsulated in smart lipoic acid-crosslinked hyaluronic acid nanoparticles
por: Zhong, Yinan, et al.
Publicado: (2017) -
Transcytosable Peptide-Paclitaxel Prodrug Nanoparticle for Targeted Treatment of Triple-Negative Breast Cancer
por: Wang, Longkun, et al.
Publicado: (2023) -
Co-delivery of gemcitabine and paclitaxel plus NanoCpG empowers chemoimmunotherapy of postoperative “cold” triple-negative breast cancer
por: Guo, Beibei, et al.
Publicado: (2023)